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PPPM), the propensity score method was less robust against unobserved confound-
ing factors than the doubly robust estimation method.
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Objectives: To compare health care costs between type 2 diabetes mellitus 
(T2DM) patients newly initiating exenatide once weekly (exenatide QW), exena-
tide twice daily (exenatide), or liraglutide (LIRA). MethOds: This administra-
tive claims-based retrospective cohort study included patients if they had T2DM, 
were GLP-1RA-naïve, initiated a GLP-1RA between 2/1/2012-6/30/2012 (initiation 
date= index), were aged ≥ 18 years, and had continuous enrollment for 12 months 
before (baseline) to 6 months after index (follow-up). Outcomes included health 
care costs (Total/Diabetes-related/GLP-1RAs) and hospitalizations (Total/Diabetes-
related). Diabetes-related outcomes included those associated with antidiabetes 
medications and medical claims coded with T2DM ICD-9-CM codes. Outcomes were 
compared between index GLP-1RAs using multivariable generalized linear models. 
Pre-specified sensitivity analyses were performed stratifying by LIRA 1.2mg and 
LIRA 1.8mg and among patients with ≥ 60 days’ supply of their index GLP-1RA within 
≤ 67 days after index (initial adherers). Results: The study sample included 1,610 
exenatide QW, 2,690 exenatide, and 6,499 LIRA patients. In multivariable-adjusted 
models, health care costs varied widely across GLP-1RAs and analyses, with exena-
tide generally being associated with the lowest adjusted health care costs (cost 
ratios vs. exenatide QW ranging from 0.762 [p< 0.001] for GLP-1RA costs to 0.908 
[p< 0.001] for Total costs among initial adherers). LIRA 1.8mg was generally associ-
ated with the highest adjusted health care costs (cost ratios vs. exenatide QW rang-
ing from 1.039 [p= 0.080] for Total costs to 1.157 [p< 0.001] for GLP-1RA costs among 
initial adherers). LIRA 1.2mg was generally associated with the highest adjusted 
odds of hospitalizations (odds ratios vs. exenatide QW ranging from 1.312 [p= 0.317] 
for diabetes-related hospitalizations to 1.528 [p< 0.036] for total hospitalizations 
among initial adherers). cOnclusiOns: Among patients newly initiating exenatide 
QW, exenatide, or LIRA, differences existed in health care costs and hospitalization 
in first 6 months of treatment. LIRA 1.8mg and 1.2mg were generally associated 
with the highest adjusted health care costs and odds of hospitalization, respectively.
PDB40
comParative cost analysis for treating growtH Hormone 
Deficience in Brazil: Pen versus syringes
Silva M.A.1, Mello I.M.1, Fernandes R.A.1, Almeida B.G.B.1, Manfrin D.F.2, Ferreira C.N.2
1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil
Objectives: To compare costs of two delivery systems (pen vs. vials/syringes) 
of recombinant human growth hormone (rGH) in Brazilian GH deficient 
patients. MethOds: A budgetary impact model was developed to calculate total 
costs based on product waste (difference between prescribed dose and actual deliv-
ered dose, based on dosing increments for pens [Pfizer Gocquick 16UI and 36UI – P16 
and P36, respectively] and a fixed-percent waste described in the literature for vials 
[Hormotrop 4UI and 12UI – V4 and V12, respectively]) and drug cost. Annual acquisi-
tion costs were calculated based upon total milligrams delivered, for pediatric and 
adult patients. Dose was 0,03mg/kg/day for children and 0,15mg/day for adults. It 
was considered both public and private payer perspectives. Results: For children, 
calculated waste was 2.56% and 7.69% for P16 and P36, respectively; for adults, it was 
0% for both versions. Waste for vials was fixed in 23% for all scenarios. From the pub-
lic payer perspective, total cost per treatment-year for children was BRL26,256.96, 
BRL25,396.38, BRL33,702.73 and BRL32,683.92 for P16, P36, V4 and V12, respectively 
and waste cost was BRL2,019.77, BRL1,953.57, BRL7,751,63 and BRL7,517.30; for 
adults, total cost per treatment-year was BRL3,750.99, BRL3,628.05, BRL5,185,04 
and BRL5,028.30 for P16, P36, V4 and V12, respectively and waste cost was BRL0.00, 
BRL0.00, BRL1,192.56 and BRL1,156,51. From the private payer perspective, total cost 
per treatment-year was, respectively, BRL32,027.03, BRL32,526.11, BRL43,164.19 and 
BRL41,858.67 for P16, P36, V4 and V12, and waste cost was BRL2,586.80, BRL2,502.01, 
BRL9,927.76 and BRL9,627.49 in children; for adults, total cost per treatment-
year was BRL4,804.05, BRL4,646.59, BRL6,640.64 and BRL6,439.79 for P16, P36, 
V4 and V12, respectively and waste cost was BRL0.00, BRL0.00, BRL1,527.35 and 
BRL1,481.15. cOnclusiOns: For pediatric and adult patients, rGH administration 
through pens was less costly, and had less waste than vials/syringes, from both 
public and private perspectives. P36 use was the best option in this analysis.
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Objectives: Uncontrolled type 2 diabetes mellitus (T2DM) increases the risk of 
chronic kidney disease (CKD). This study examined the health care resource utili-
zation (HRU) and costs among T2DM patients with varying degrees of CKD using 
electronic health records. MethOds: This retrospective study was conducted using 
electronic health records from US integrated delivery networks from 2008 to 2012. 
Adult T2DM patients (first T2DM diagnosis denotes index date) with continuous 
medical activity during the 6-month pre- and 12-month post-index period and lab 
values for CKD classification were selected. CKD stages were assessed using the 
estimated glomerular filtration rate and urine albumin to creatinine ratio. HRU/costs 
by CKD stage (Stages 1, 2, 3A, 3B, and 4) were captured from the 12-month follow-up 
data and compared to T2DM patients without CKD (no CKD). Unit cost approach was 
applied to derive medical encounter costs. Multivariate regression analyses were 
Objectives: Patients who do not incorporate diet modifications in their therapy 
regimen may create an undesirable escalation in blood glucose level leading to 
hyperglycemia and chronic complications. The objective of this study is to investi-
gate the prevalence of diabetic patients who incorporate diet modification in their 
therapy, and its association with health care utilization and expenditures for the 
U.S. civilian noninstitutionalized population. MethOds: Our study was conducted 
with a quasi-experimental design approach. Subjects included were patients who 
reported being diagnosed with diabetes and reported the treatment of diabetes 
with diet modification from the 2011 Medical Expenditure Panel Survey. A series of 
weighted inferential statistics were used to test the effect of diet modification on 
the variables associated with health care use and expenditures. All analyses were 
accomplished by taking into consideration MEPS sample adjustments using SAS 
9.3. Results: There were an estimated 21.8 million who have been diagnosed with 
diabetes in the US in 2011, of which, 4.6 million (21%) did not include diet modifica-
tion in their therapy. For total health care expenditures, those who did not include 
diet modification had more expenditure (M = $11,230, SE = 811.84) comparing with 
those who included diet modifications (M = $10,638, SE = 487.25), t (172) = 25.26, 
p< .0001. Moreover, total inpatient expenditure for those who did not include diet 
modification (M = $3,003, SE = 497.3) and patients who included diet modification 
(M = $2545.66, SE = 251.45), revealed a significant difference between the groups; t 
(172) = 12.33, p< .0001. cOnclusiOns: The study findings indicated that diabetic 
patients with diet modification had significant lower utilization and expenditures. 
Regulating diet is extremely important for people who have diabetes. It can be very 
effective in preventing or postponing the progression of diabetes, and subsequently 
managing the cost and utilization associated with it.
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Objectives: To determine cost savings related to growth hormone (GH) treatment 
and impact on height outcome when a data-driven approach is used, compared to 
conventional treatment approach based on experience, in pre-pubertal patients 
with growth hormone deficiency (GHD) and Turner syndrome (TS). MethOds: A 
model had been developed previously to study height outcome and total GH cost 
in the presence or absence of data-driven treatment decisions. The proportion of 
patients for whom height outcome could be improved or GH use could be reduced 
(i.e. for low compliance, or high or low responders) was estimated using a cohort 
from the Pfizer International Growth Database (KIGS). This model was adapted to 
Brazilian patients, for both private and public perspectives, resulting in 4 scenarios: 
(1) Genotropin 16UI private, (2) Genotropin 36UI private, (3) Genotropin 16UI public 
and (4) Genotropin 36UI public. Eligible patients were calculated by applying local 
prevalence rates to infant population (n= 13,686 GHD and 15,641 TS). The analysis 
used a 4-year time horizon. Effects were defined as height outcome after 4 years 
and total treatment cost. Results: The analysis estimated that the data-driven 
approach could reduce total cost of GH therapy by 7.1% over 4 years for the treat-
ment of Brazilian patients with GHD and by 6.7% for patients with TS, representing 
a reduction of 7.0% for all subjects. Total costs for all scenarios, when the conven-
tional approach is used were: (1) BRL3,572,931,540.80, (2) BRL3,455,666,095.35, (3) 
BRL2,789,533,217.78 and (4) BRL2,698,326,760.21; with the data-driven approach, total 
costs were: (1) BRL3,327,729,748.47, (2) BRL3,218,511,951.60, (3) BRL2,598,094,188.81 
and (4) BRL2,513,147,013.46. Despite the reduction in treatment costs, the average 
height remained unaffected. cOnclusiOns: In Brazil, the data-driven approach 
could be a useful tool to guide treatment decisions for children with GHD and TS. 
Total costs of GH treatment could be reduced, without having an impact on growth 
outcomes.
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Objectives: To compare the doubly robust estimation and propensity score meth-
ods in a diabetes-related comparative health economics study. MethOds: We used 
large US claims databases that covered 115 million patients between 2000 and 2011. 
Patients with type 2 diabetes with continuous health insurance were selected into 
the intensification cohort or non-intensification cohort depending on whether they 
intensified basal insulin with insulin aspart or remained on treatment with basal 
insulin without bolus insulin. The study measured the patients’ demographic and 
clinical characteristics, as well as their health care utilization and medical costs in 
a 6-month pre-baseline period and a 12-month post-baseline period. Doubly robust 
estimation and propensity score methods were used to examine the impact of inten-
sification on direct medical costs per patient per month (PPPM). Results: The study 
included 26,016 qualified patients with 2,860 in the intensification cohort and 23,156 
in the non-intensification cohort. Baseline characteristics were similar between 
the two cohorts (mean age= 58 years, percentage male= 52%). Both cohorts also had 
similar prevalence rates of diabetes-related conditions, and similar utilization and 
medical costs in the pre-baseline period. The propensity score method indicated 
that the intensification cohort spent $297.4 PPPM less in the post-baseline period 
than the non-intensification cohort (p< 0.05), while the doubly robust estimation 
method estimated a $399.0 PPPM cost reduction due to treatment intensification 
(p< 0.05). The doubly robust estimation method was able to control all confounding 
factors also controlled by the propensity score method, as well as additional con-
founding factors not controlled by the propensity score method. cOnclusiOns: 
Although both the propensity score and doubly robust estimation methods revealed 
cost savings due to treatment intensification with insulin aspart ($297.4 vs. $399.0 
